INS and Alzheimer disease: However, its clinical efficacy requires further validation.471 NE3107 (25, formerly HE3286) is a small insulin sensitizer that inhibits inflammation.425 A phase III clinical trial (NCT04669028) has been completed, aimed at testing the safety and efficacy of the drug in elderly patients with mild to moderate AD.